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ABSTRACT
Glioblastoma multiforme (GBM) is the most common and aggressive brain tumor 
with limited therapeutic options. Glioma stem cell (GSC) is thought to be greatly 
responsible for glioma tumor progression and drug resistance. But the molecular 
mechanisms of GSC deriving recurrence and drug resistance are still unclear. SOX9 
(sex-determining region Y (SRY)-box9 protein), a transcription factor expressed in 
most solid tumors, is reported as a key regulator involved in maintaining cancer 
hallmarks including the GSCs state. Previously, we have observed that silencing of 
SOX9 suppressed glioma cells proliferation both in vitro and in vivo. Here, we found 
that SOX9 was essential for GSC self-renewal. Silencing of SOX9 down-regulated 
a broad range of stem cell markers and inhibited glioma cell colony and sphere 
formation. We identified pyruvate dehydrogenase kinase 1 (PDK1) as a target gene 
of SOX9 using microarray analyses. PDK1 inactivation greatly inhibited glioma cell 
colony and sphere formation and sensitized glioma spheres to temozolomide (TMZ) 
toxicity. In addition, SOX9-shRNA and PDK1 inhibitor could greatly sensitize GSC to 
TMZ in vivo. Taken together, our data reveals that SOX9-PDK1 axis is a key regulator 
of GSC self-renewal and GSC temozolomide resistance. These findings may provide 
help for future human GBM therapy.
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 INTRODUCTION
Glioblastoma multiforme (GBM) is regarded as 
one of the most common intracranial primary tumors. 
For years, conventional therapeutic strategies including 
surgery, radiation and chemotherapy targeting the bulk 
of tumor have acquired limited benefits, with the median 
survival hardly improved [1]. Recurrence of malignant 
tumor is one of the leading causes of cancer patients’ 
death and one of the biggest challenges in cancer 
treatment currently. Although biotechnology helps people 
understand cancer more than before, the primary cause of 
tumorigenesis, recurrence is still unclear. As the culprit 
who accounts for the relapse and therapeutic resistance, 
the small group called “glioma stem-like cell” (GSC) 
demonstrates many features as neural stem cells like sphere 
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formation [2–5], self-renewal and differentiation and has 
been thought to be the potential cause of tumor recurrence 
during glioma cancer therapy [6]. Hence, specific targeted 
therapies aiming at elimination of GSC would render great 
significance to therapeutic advancement of GBM.
Sex-determining region Y (SRY)-box9 protein 
(SOX9) is a transcription factor that controls cell fate 
decision during the development and homeostasis of a 
broad range of tissues, and is expressed in a wide range 
of cancers [7–10]. SOX9 deletion prevents tumorigenesis 
in prostatic and pancreatic mouse cancer models [11, 12]. 
Overexpression of SOX9 inhibits apoptosis and promotes 
proliferation, invasion, and migration, whereas down-
regulation of SOX9 impaired invasion and growth in 
vitro and in vivo [13–15]. SOX9 has been well recognized 
for its capacity in stemness maintenance of neural stem 
cell (NSC). Gain- and loss-of-function studies indicated 
that SOX9 was essential for multipotent NSC formation. 
Moreover, sonic Hedgehog was able to stimulate 
precocious generation of NSCs by inducing SOX9 
expression [16]. SOX9 has been also well characterized 
for its oncogenic potency in many aspects of cancer 
stemness [9], such as promoting tumor initiation and 
invasion, maintaining the self-renewal of CSCs [17]. 
However, the mechanism for aberrant up-regulation of 
SOX9 in GBM remains elusive. 
In this article, we found that SOX9 mRNA was 
overexpressed and positively correlated with the protein 
level in GBM. Knockdown of SOX9 in GBM cell lines 
markedly suppressed the stem cell-like properties, including 
stem cell marker expression level and glioma cell sphere 
formation, indicating that SOX9 was essential for GSC 
self-renewal. We also found that pyruvate dehydrogenase 
kinase 1 (PDK1) was a downstream target of SOX9 
through microarray analyses, and the activity of PDK1 
was essential for GSC self-renewal in GBM. Inactivation 
of PDK1 greatly inhibited glioma cell sphere formation. 
In addition, PDK1 inactivation greatly sensitized glioma 
sphere to temozolomide. The level of phosphorylation AKT 
was regulated by PDK1 activity, which was important for 
GSC temozolomide resistance. Collectively, these results 
indicated that SOX9-PDK1 axis was a critical regulator of 
GSC self-renewal and played important role in GBM drug 
resistance.
RESULTS
SOX9 was overexpressed both at the mRNA level 
and protein level in GBM 
To investigate the candidate role of SOX9 in GBM, 
we firstly interrogated the data of SOX9 by bioinformatics 
using TCGA database and Human protein Atlas. We found 
that the mRNA level of SOX9 was markedly higher in 
GBM tissues compared with normal brain from the 542 
GBM samples in TCGA database (http://tcga-data.nci.
nih.gov) (Figure 1A). The protein levels of SOX9 were 
majority high in most GBM sample in Human protein 
Atlas (http://www.proteinatlas.org). Nest, the protein 
expression of SOX9 was detected in four GBM tissues and 
the couple normal brain tissues. Western blotting analyzing 
verified that SOX9 expressed significant higher in GBM 
tissues than normal brain tissues (Figure 1B and 1C). 
Then, the SOX9 expression level was also detected in 
U251 and U87 GBM cell lines and HEB, and the result 
showed that the level of SOX9 was higher in both U251 
cells and U87 cells than in HEB cells (Figure 1D and 1E). 
On the whole, these data reflected that SOX9 was 
overexpressed in human GBM.
SOX9 was at high expression in glioma stem cell-
like sphere
Stem cell-like sphere was a common model 
frequently used in stem cell studies. To verify the potential 
role of SOX9 in glioma stem cells, sphere formation assay 
was processed using U251MG and U87MG cell lines 
(Figure 2A). Data showed that mRNA level of SOX9 
was obviously higher in spheres than in monolayers 
(Figure 2B). Simultaneously, levels of several stem cell 
makers SOX2 (Figure 2C), NESTIN (Figure 2D), Oct-4 
(Figure 2E) and NANOG (Figure 2F), were all higher 
compared with in monolayers. These results indicated 
that the level of SOX9 and stem cell marker increased in 
glioma spheres.
SOX9 knockdown inhibits glioma cell colony 
formation and stem cell-like properties
To determine the biological function of SOX9 in 
glioma stemness, we applied shRNAs against SOX9 to 
U251 and U87MG cells, and found that SOX9-shRNAs 
significantly decreased SOX9 protein expression in U251 
(Figure 3A and 3B) and U87MG cells (Figure 3C and 3D). 
The stable cell lines constructed by SOX9-shRNAs 
lentivirus (LV3-GFP) were subsequently applied in the 
colony formation and sphere formation assay. Stably 
expressing SOX9 shRNA significantly decreased the 
colony formation ability both in U251MG (Figure 3E and 
3F) and U87MG (Figure 3G and 3H) compared to those 
cell lines stably expressing negative control shRNA. The 
sphere-forming units (SFU) and diameter of spheres were 
detected to access the effect of SOX9 knockdown on glioma 
sphere formation. Result showed that SOX9 knockdown 
significantly decreased the SFU and diameter of spheres in 
U251MG (Figure 3I, 3J and 3K) and U87MG (Figure 3L, 
3M and 3N) compared to their negative controls. Moreover, 
clone-forming ability at a single cell level was markedly 
inhibited by treatment with SOX9 shRNA compared with 
the control shRNA both in U251 (Figure 3O) and in U87 
cells (Figure 3P). These founding demonstrated that SOX9 
was essential for glioma cell stemness.
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In addition, knockdown of SOX9 in U251MG and 
U87MG cell lines decreased the mRNA level of stem cell 
markers CD133, NESTIN and SOX2 in both U251MG 
(Figure 4A) and U87MG (Figure 4B) cell lines. Protein 
level of NESTIN and SOX2 was also decreased in both 
U251MG (Figure 4C and 4D) and U87MG (Figure 4E 
and 4F) cell lines after SOX9 was silenced. Taken together, 
the above results indicated that SOX9 was a putative 
cancer stem marker in GBM cells and was essential for 
glioma stem cell properties.
PDK1 is a downstream target of SOX9
Given that the SOX9 was involved in glioma stem 
cell-like properties, we were interested in the relevant 
downstream genes regulated by SOX9 in glioma. There 
were a total of about 194 genes with at least a 1.5-fold 
change mutually regulated by SOX9 in U251 cells by both 
two SOX9-shRNA1 and SOX9-shRNA2 (Figure 5A). 
Pathway analysis of the 194 common regulated genes 
revealed the most significant enrichment in several core 
signaling pathways (Figure 5B). We firstly confirmed the 
fidelities of microarray results by analyzing the mRNA 
expression of nine most down-regulated genes with qRT-
PCR (Figure 5C), which were tightly associated with 
cancer stem cell stemness or glioma tumorigenesis. Data 
of qRT-PCR showed that expression levels of these genes 
were found to be consistent with that in the microarray data 
in U251 cells and U87 cells (Figure 5D and 5E). Among 
these genes, we chose PDK1 as the target downstream 
of SOX9, which exhibited the most change in SOX9 
knockdown cells. Protein expression of PDK1 was detected 
in four GBM tissues and the couple normal brain tissues. 
Result showed that PDK1 expressed significant higher in 
GBM tissues than normal brain tissues (Figure 5F and 5G). 
Then, the PDK1 expression level was also detected in U251 
and U87 GBM cell lines and HEB, and the result showed 
that the level of PDK1 was higher in both U251 cells and 
U87 cells than in HEB cells (Figure 5H and 5I). Western 
blot analysis also indicated that PDK1 was significantly 
decreased in U251 (Figure 5J and 5K) and U87 (Figure 5L 
and 5M) cells. In a summarization, these results underlined 
that PDK1 was a downstream target of SOX9.
Inactivation of PDK1 inhibited glioma cell 
colony formation and sphere formation
On account of that PDK1 is a normal upstream of 
AKT pathway, and AKT pathway is an important regulator 
in cancer stem cell. So we speculated that PDK1 might be 
a potential target in SOX9 stemness regulating. To detect 
the role of PDK1 in glioma stemness, the activity of PDK1 
Figure 1: SOX9 was overexpressed both at the mRNA level and protein level in GBM. (A) Relative mRNA expression of 
SOX9 in normal brain and GBM samples TCGA database. (B) Western blots analysis for protein expression of SOX9 in patients’ tissue 
samples. P represented for normal tissue, C represented for GBM tissue. (C) Box plots of SOX9 expression in tissue samples. (D) Western 
blots analysis for protein expression of SOX9 in U251, U87 and HEB cell lines. (E) Quantitation of SOX9 expression in U251, U87 and 
HEB cell lines. The densitometry data were expressed as the mean±SD of three independent experiments. **P < 0.01, and ***P < 0.001 
versus relative control.
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was inhibited by a PDK1-specific inhibitor OSU03012. 
First, we verified that the protein expression of PDK1 was 
decreased in SOX9-knockdown U251MG (Figure 5E) 
and U87MG cells (Figure 5G). Then we found that cell 
viabilities of U251MG and U87MG were decreased by 
OSU03012 (Figure 6A and 6B). Then colony formation 
and sphere formation assay were performed to see the 
effect of OSU03012 in glioma cell growth and glioma 
stemness. Data showed that the colony formation capacities 
was significant decreased in both in U251MG (Figure 6C 
and 6D) and U87MG (Figure 6E and 6F) when exposing 
in OSU03012 compared with the negative controls. While 
the PDK1 activator PS48 didn’t reveal effect to glioma cell 
colony formation (Supplementary Figure 1A–1D). Sphere 
formation assay showed that OSU03012 could effectively 
inhibit sphere formation of U251MG (Figure 6G–6I) and 
U87MG (Figure 6J–6L) cell lines. Meanwhile, the mean 
diameter of the spheres was smaller when exposing with 
OSU03012. Interestingly, PS48 also had no influence to the 
sphere formation capacity to glioma cells (Supplementary 
Figure 2A–2E).
PDK1 inactivity sensitized GSC to TMZ 
treatment both in vitro and in vivo
To determine whether PDK1 activity was related 
with temozolomide (TMZ) resistance of glioma stem cell, 
glioma GSCs were incubated with serial dilutions of TMZ 
with or without PDK1 inhibitor OSU03012 and PDK1 
activator PS48, then GSC spheres number and size were 
evaluated. The results showed that the spheres number of 
GSC treated with TMZ and OSU03012 was obviously 
decreased that only treated with TMZ both in U251-GSC 
(Figure 7D and Supplementary Figure 3E) and U87-GSC 
(Figure 7E and Supplementary Figure 3F). The effect of 
PDK1 activity on GSC cell apoptosis was investigated 
by PI/Hoechst staining. The treatment combined of 100 
μmol/L TMZ and 1 μmol/L or 10 μmol/L OSU03012 for 
12 h induced substantial apoptosis in U251MG (Figure 
7A) and U87MG (Supplementary Figure 3) GSCs, while 
100 μmol/L TMZ alone only caused a very slight cell 
apoptosis. The effect of TMZ on GSC apoptosis was 
consistent with SOX9-shRNAs, data showed that there 
Figure 2: SOX9 was at high expression in glioma stem cell-like sphere. (A) Representative images for spheres of U251MG and 
U87MG cells. Magnification, ×200. (B–F) qRT-PCR detection for expression of SOX9, SOX2, NESTIN, Oct-4, NANOG, respectively. 
The densitometry data were expressed as the mean ± SD of three independent experiments. ***P < 0.001 versus normal U87 or U251 cells.
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were apparent more PI positive cell in GSC that co-treated 
with 100 μmol/L TMZ and SOX9 shRNA1 for 12 h than 
GSC that single treated with TMZ or SOX9 (Figure 7B 
and Supplementary Figure 3B). OSU03012 alone could 
also induce U251MG and U87MG GSC apoptosis 
(Supplementary Figure 3C and 3D), but the treatment 
time must be more than 48 h, which was much longer 
than combination of TMZ and OSU03012. Moreover, the 
combination of PS48 and TMZ didn’t induce cell apoptosis 
increase U87MG in GSCs (Supplementary Figure 4), 
indicating that PDK1 activation could enhance GSC 
resistance to TMZ. Finally, the effect of PDK1 activity 
or SOX9 expression level on GSC was assessed in vivo 
using nude mice. The result showed that the tumor treated 
Figure 3: SOX9 knockdown inhibited glioma cell colony formation and sphere formation. (A) The efficiency validation 
of SOX9-shRNAs by immunoblotting in U251 cells. (B) Quantitation of SOX9 expression in SOX9 knockdown and control U251 cells. 
(C) The efficiency validation of SOX9-shRNAs by immunoblotting in U87 cells. (D) Quantitation of SOX9 expression in SOX9 knockdown 
and control U87 cells. (E) The morphology of cell colonies formed by SOX9 knockdown U251 cells. (F) Number of cell colonies formed 
by SOX9 knockdown and control U251 cells. (G) The morphology of cell colonies formed by SOX9 knockdown U87 cells. (H) Number 
of cell colonies formed by SOX9 knockdown and control U87 cells. (I) Represent images of U251-SOX9 knockdown spheres. (J) Effect 
of SOX9 knockdown on the number of Sphere Forming Units (SFU) of U251 cells. (K) Diameters of glioma spheres decreased in SOX9 
knockdown U251 spheres, Arabic numerals represented for spheres number. (L) Represent images of U87-SOX9 knockdown spheres. (M) 
Effect of SOX9 knockdown on the number of SFU of U87 cells. (N) Diameters of glioma spheres decreased in SOX9 knockdown U87 
spheres, Arabic numerals represented for spheres number. (O) Single sphere growth in SOX9 knockdown U251MG. (P) Single sphere 
growth in SOX9 knockdown U87MG. Data were expressed as the mean ± SD of three independent experiments. Figures presented are the 
representative of at least three independent experiments. **P < 0.01, and ***P < 0.001 versus NC.
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by TMZ combined with SOX9 shRNA or PDK1 inhibitor 
grew much slower that TMZ single, indicating that SOX9 
shRNA and PDK1 inhibitor could significant enhance the 
suppressing effect of TMZ on nude mice tumor growth 
(Figure 7C). Taken together, PDK1 inactivity sensitized 
GSC to TMZ treatment both in vitro and in vivo.
In human glioma, PI3K-AKT signaling promotes 
cell growth, cell survival and glioma stem cell property 
by several mechanisms, and AKT pathway is reported 
to a key axis in glioma stemness and tumorigenesis 
[20]. So we detected the change of AKT to determine 
whether OSU03012 induced GSC apoptosis by regulate 
AKT pathway. Western blotting analysis showed that the 
expression of p-PDK1 and p-AKT in GSCs were down-
regulated after disposed in OSU03012 both in U251MG 
(Figure 8A–8C) and U87MG (Figure 8D–8F), indicating 
that the inhibition of AKT pathway was the regulator 
for PDK1 facilitating TMZ sensitization. Together, the 
above results indicated that SOX9-PDK1 axis was a key 
regulator for glioma stem cell properties which were 
PI3K-AKT pathway dependently.
DISCUSSION
SOX9 belongs to group E (SOX8, SOX9, and 
SOX10) of the SOX transcription factor family defined 
by a common HMG box domain originally identified in 
SRY, the sex-determining gene on the Y chromosome 
[21]. SOX9 has roles in epithelial invasion, migration, and 
proliferation and plays important roles in multiple types of 
cancers [22–24]. What’s interest is that SOX9 is regulated 
by many upstream pathway including EGFR, Notch, Wnt 
and sonic hedgehog pathways [25–28]. These pathways 
were reported to be associated with CSC regulation. In 
GBM, SOX9 protein expression suppressing in the glioma 
cell lines was reported displayed loss of cell adhesion, 
inhibition of AKT phosphorylation and G1 arrest [29]. 
These studies prompt SOX9 may be a critical regulator in 
glioma tumorigenesis.
PI3Ks are a family of heterodimeric lipid kinases 
composed of catalytic and regulatory subunits that, on 
stimulation, catalyze production of the second messenger 
phosphatidylinositol-3,4,5-triphosphate (PIP3). Recent 
studies have reported that PI3K-AKT pathways can be 
activated by SOX9. SOX9 directly binds to the promoter 
region of the PI3K subunit gene Pik3ca (also known as 
p110, one of three subunit proteins of PI3K), enhancing 
the phosphorylation of AKT [30]. PI3K generates 
phosphatidylinositol (3,4,5)-trisphosphate [PtdIns(3,4,5)P3] 
from PtdIns(4,5)P2. PtdIns(3,4,5)P3 causes phosphorylation 
of and activates AKT [31]. PDK1 is also a downstream 
kinase of PI3K, and it can be activated by PI3K. PIP3 brings 
PDK1 and AKT to the membrane, where PDK1 activates 
AKT by phosphorylation at residue threonine 308 [32, 33]. 
Figure 4: SOX9 regulated the expression of stem cell markers in glioma cells. (A) qRT-PCR detection for expression of SOX9, 
SOX2, NESTIN, CD133 in U251MG. (B) qRT-PCR detection for expression of SOX9, SOX2, NESTIN, CD133 in U87MG. (C) Western 
blot analysis for expression of SOX9, SOX2 and NESTIN in SOX9 knockdown and control U251 cells. (D) Quantitation of the expression 
of SOX9, SOX2 and NESTIN in SOX9 knockdown and control U251 cells. (E) Western blot analysis for expression of SOX9, SOX2 
and NESTIN in U87 cells. (F) Quantitation of the expression of SOX9, SOX2 and NESTIN in SOX9 knockdown and control U87 cells. 
The densitometry data were expressed as the mean ± SD of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 versus NC.
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In human glioma, PI3K-AKT signaling promotes cell 
growth, cell survival and glioma stem cell property by 
several mechanisms [34]. But the role of SOX9-PDK1 
signaling in glioma tumorigenesis and glioma stem cell has 
not been reported.
In this paper, SOX9 was demonstrated to be a key 
regulator in glioma tumorigenesis and GSC self-renewal. 
For a deep exploration of the downstream gene spectrum 
of SOX9, we screened through Gene Expression Chip to 
find the list of differentially expressed genes regulated by 
SOX9. PDK1 is indicated the downstream target of SOX9 
that showed similar function with SOX9 in GSC self-
renewal and TMZ resistance. Our data showed that SOX9 
and PDK1 exhibited the similar function in glioma colony 
formation and sphere formation. What’s more, SOX9 
knockdown could remarkably decrease the level of p-PDK1 
and p-AKT, while PDK1 inactivation could also decrease 
the level of p-AKT. Due to the important role of PI3K/
AKT in both cancer progression and stem cell self-renewal 
[29, 30], it is reasonable that SOX9-PDK1 axis might be 
very important in glioma stemness properties. Meanwhile, 
our data proved that SOX9 knockdown and PDK1 
inactivation both greatly decreased GSC stemness and 
sensitized GSC to TMZ treatment. Thus, we constructed the 
theory that SOX9-PDK1 axis regulated GSC self-renewal 
and GSC TMZ resistance by regulating the activation of 
PI3K-AKT pathway (Figure 8G). This is the first time 
that SOX9-PDK1 axis is indicated as a key regulator in 
glioma stem cell maintenance. Considering the versatile 
functions of SOX9 in cancer biology, further research 
such as expression profile and proteomic analysis will be 
conducted to explore the entire mechanism framework of 
SOX9 on the regulation of cancer stemness in the future.  
In a conclusion, our work provides a new insight 
into the maintenance mechanism of glioma stemness by 
uncovering the novel SOX9-PDK1 axis, and intervention 
of which will be a promising alternative approach for the 
radical cure of GBM.
Figure 5: PDK1 is a downstream target of SOX9. (A) Venn diagram showing the intersection of genes between: genes that 
were downregulated and upregulated 1.5-fold or more in SOX9 knockdown U251 cells. (B) Pathway enrichment analysis for 506 genes 
identified from SOX9-shRNA1 and SOX9-shRNA2. (C) Representative genes that were found to be downregulated in Microarray 
analyses. (D) qRT-PCR validation of 8 mutually regulated gene in knockdown U251 cells. (E) qRT-PCR validation of 8 mutually regulated 
gene in knockdown U251 cells. (F) Western blots analysis for protein expression of PDK1 in patients’ tissue samples. P represented for 
normal tissue, C represented for GBM tissue. (G) Box plots of PDK1 expression in tissue samples. (H) Western blots analysis for protein 
expression of PDK1 in U251, U87 and HEB cell lines. (I) Quantitation of PDK1 expression in U251, U87 and HEB cell lines. (J) Western 
blot analysis verified the expression of PDK1 in SOX9 knockdown and control U251 cells. (K) Quantitation of the expression of PDK1 
in SOX9 knockdown and control U251 cells. (L) Weatern blot analysis verified the expression change of PDK1 in SOX9 knockdown U87 
cells. (M) Quantitation of the expression of PDK1 in SOX9 knockdown and control U87 cells.The densitometry data were expressed as the 
mean ± SD of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 versus NC.
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Figure 6: Inactivation of PDK1 inhibited glioma cell colony formation and glioma sphere formation. (A) Cell viability 
of U251 cells exposing in OSU03012. (B) Cell viability of U87 cells exposing in OSU03012. (C) The morphology of U251 cell colonies 
formed by OSU03012. (D) Number of cell colonies formed by OSU03012 in U251 cells. (E) The morphology of U87 cell colonies formed 
by OSU03 012. (F) Number of cell colonies formed by OSU03012 in U87 cells. (G) The morphology of tumor spheres formed by the glioma 
stem-like cells from control U251 and OSU03012 in U251 cells. (H) Effect of OSU03012 on the number of Sphere Forming Units (SFU) 
of U251 cells. (I) Effect of OSU03012 on the size of U251 GSCs, Arabic numerals represented for spheres number. (J) The morphology of 
tumor spheres formed by the glioma stem-like cells from control U87 and OSU03012 U87 cells. (K) Effect of OSU03012 on the number 
of Sphere Forming Units (SFU) of U87 cells (L) Effect of OSU03012 on the size of U87 GSCs, Arabic numerals represented for spheres 
number. Error bars represent SD. The densitometry data were expressed as the mean ± SD of three independent experiments. *P < 0.05, 
**P < 0.01, ***P < 0.001 versus non-treated cells.
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MATERIALS AND METHODS
Human GBM tissue preparation 
Human GBM samples were obtained from surgery 
operations in Tangdu Hospital in Xi’an. The normal brain 
tissues were obtained from the patients of traumatic brain 
edema that underwent partial brain resection, which were 
preserved in liquid nitrogen. All procedures related to 
acquiring patient samples were approved by the ethics 
committee of Tangdu Hospital Institutional Review 
Board. The tissues were broken by homogenizer, then total 
mRNA and protein were extracted.
Cell lines and sphere formation assay
The HEB, U251MG and U87MG cell lines were 
purchased from the Chinese Academy of Sciences Cell 
Bank [18]. The authenticity of cancer cell lines was 
tested by short tandem repeat profiling. All cell lines were 
grown in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% FBS (Gibco, USA). Glioma 
stem-like cells (GSCs) were cultured and isolated from 
U251 and U87MG glioma cell lines by using serum-free 
medium (SFM) which was supplemented with 20 ng/mL 
basic fibroblast growth factor (bFGF; Sigma-Aldrich, 
USA), 20 μL/mL B27 supplement (Life Technologies), 
and 20 ng/mL EGF (Sigma-Aldrich, USA). The medium 
was refreshed every 2 days. After 10 days, the tumor 
spheres diameters larger than 50 μm were counted and 
photographed using phase contrast microscope [19]. The 
number of Sphere Forming Units (SFU) is calculated 
according to the following formula: SFU = (number of 
spheres counted/number of input cells) × 100.
Lentivirus transfection and colony formation 
assay
Stable shRNA-expressing U251 and U87MG 
cell lines were established by puromycin screening 
at a concentration of 2 μg/mL for about two weeks 
to screen stably transfected U251 and U87MG cells 
with SOX9 shRNA and control shRNA. The target 
sequences are NC: TTCTCCGAACGTGTCACGT; 
SOX9 KD1: GCATCCTTCAATTTCTGTATA; SOX9 KD1: 
CTCCACCTTCACCTACATGAA. For clonogenicity, 1 × 103 
cells were seeded in 60 mm petri dish. After about 7 to 
10 days culturing, colonies were dyed by crystal violet 
and the colonies number was calculated and collected for 
statistical analysis.
Quantitative RT-PCR
Total RNA from glioma cells was isolated using 
TRIzol reagent (Invitrogen, USA). The RNA was 
subsequently treated with RNase-free DNase I (Roche, 
Figure 7: PDK1 and SOX9 knockdown sensitized GSC to TMZ in vitro and in vivo. (A) PI/Hoechst assay of U251MG sphere 
treated with TMZ and OSU03012. (B) PI/Hoechst assay of U251MG-SOX9 KD1 sphere treated with TMZ. (C) Growth curves of different 
groups of nude mice xenograft tumor. (D) Number of Sphere Forming Units (SFU) of U251 GSC with different treatment. (E) The size of 
U251 GSC with different treatment, Arabic numerals represented for spheres number.
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Switzerland). Synthesis of cDNA was done by using the 
BcaBest RNA PCR kit from TaKaRa (Japan) according 
to the manufacturer’s instructions. Quantitative RT-PCR 
was carried out using the iQ5 Multicolor Real-Time 
PCR Detection System (Bio-Rad) with Realtime PCR 
Master Mix (SYBR Green). The PCR primers are listed 
in Supplementary Table 1, β-actin was selected as the 
endogenous control in the assay.
Western blotting
The total cell lysates were prepared in RIPA 
lysis buffer with complete protease inhibitor cocktail 
(Beyotime, China). The protein concentration was 
determined using a BCA Protein Assay Kit (Beyotime, 
China). The cell lysates were added to SDS sample buﬀer 
(BioRad), boiled for 5 minutes, and separated using SDS-
Figure 8: Mechanism of SOX9-PDK1 regulation axis in GSC self-renewal and TMZ resistance. (A) Western blots analysis 
for p-PDK1, PDK1, p-AKT and AKT expression in U251MG after exposing in OSU03012 for 4 h. (B–C) Quantitation of p-PDK1/PDK1 
and p-AKT/AKT in U251MG. (D) Western blot analysis for p-PDK1, PDK1, p-AKT and AKT expression in U87MG after exposing in 
OSU03012 for 4 h. (E–F) Quantitation of p-PDK1/PDK1 and p-AKT/AKT in U87 MG. (G) Pattern diagram of SOX9-PDK1 axis in GSC 
self-renewal and TMZ resistance. The densitometry data were expressed as the mean ± SD of three independent experiments. **P < 0.01, 
***P < 0.001 versus non-treated cells.
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PAGE. The proteins were transferred onto nitrocellulose 
membranes, which were subsequently blocked in 5% milk. 
The membranes were incubated with primary antibodies 
according to the manufacturers’ protocols. The dilutions 
of primary antibodies in Western blot assay were SOX9 
(1:4000, Abcam, UK), β-actin (1:4000, Abmart, China), 
p-AKT (1:1000, Cell Signaling Technology, USA), AKT 
(1:1000, Cell Signaling Technology, USA), p-PDK1 
(1:1000, Cell Signaling Technology, USA), PDK1 
(1:1000, Cell Signaling Technology, USA), NESTIN 
(1:2000, Sigma-Aldrich, USA), SOX2 (1:1000, Sigma-
Aldrich, USA), respectively. The membranes were 
incubated with horseradish peroxidase (HRP)-conjugated 
secondary antibodies for 1 hour at room temperature. The 
immunoblots were developed using Amersham™ ECL 
(GE Healthcare), and images were acquired using the 
luminescent image analyzer LAS-4000 mini (Fujiflm, GE 
Healthcare). The western blot signal representing protein 
level was obtained by quantifcation using ImageJ software.
Temozolomide sensitive cell death assay
Glioma spheres grown in the presence of serum were 
seeded in 24-well plates. Spheres were left untreated or 
treated with TMZ (Tasly Pharmaceutical Co., Ltd., Tianjin, 
China). Then spheres were incubated in culture medium 
containing 5 mg/mL PI and 5 mg/mL Hoechst at 37°C 
for 30 min. Cell death was observed under fluorescence 
microscope, and cell death ratio was quantified by the ratio 
of PI/ Hoechst.
Microarray analyses
Total RNA was extracted using TRIzol reagent 
(Invitrogen, USA). Extracted RNA was labeled and 
hybridized onto the Agilent Human Gene Expression 
Analysis platform (8*60K, Design ID: 039494) by 
Oebiotech Co.. Statistical analyses and data normalization 
were conducted using the Genespring GX software 
(Agilent Technologies, USA). Genes with 1.5-fold change 
in expression were considered differentially regulated by 
SOX9. Genes were mapped onto KEGG pathways using 
DAVID version 6.7 (http://david.abcc.ncifcrf.gov/). 
Tumor xenografts assay
To test the anti-glioma effect of TMZ alone or in 
combination with SOX9 shRNA and PDK1 inhibitor 
OSU03012 in vivo, a xenograft model of human glioma was 
established. 4-week old male SCID mice were purchased 
from Vital River Laboratory Animal Technology Co. Ltd. 
(Beijing, China). Each mouse was injected subcutaneously 
in the right flank with 1 × 106 U87 GSCs resuspended in 200 
μL PBS. The mice of SOX9 KD group and TMZ combined 
SOX9 KD group were injected with SOX9-shRNA1 stable 
expressing U87 GSCs, and the other groups were injected 
with normal U87 GSCs. Mice were randomly divided into 
6 groups (five mice per group) and treatment was started. 
The TMZ treated concentration is 25 mg/kg/day, and the 
OSU03012 treated concentration is 15 mg/kg/day. Tumor 
diameter was measured every 2 days, and the tumor volume 
was calculated (length × width × width × 0.5).
Statistical analysis
Statistical differences were analyzed using Student’s 
t-test for unpaired samples. An ANOVA followed by the 
Dunnett’s test was used for multiple comparisons with one 
control group. The criterion for significance (p value) was 
set as mentioned in the Figure legends.
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